Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Submits NDA For Skin Spray To Treat Hot Flashs

This article was originally published in The Pink Sheet Daily

Executive Summary

EvaMist would be marketed as a more convenient form of hormone replacement than oral, gel and patch products.
Advertisement

Related Content

Vivus Sells EvaMist Rights To KV For $150 Million
Vivus Sells EvaMist Rights To KV For $150 Million
BioSante To Launch Hot Flash Drug Elestrin in 2007
BioSante To Launch Hot Flash Drug Elestrin in 2007
Vivus Could File Evamist Menopause Spray By Year-End
Vivus Could File Evamist Menopause Spray By Year-End

Topics

Advertisement
UsernamePublicRestriction

Register

PS063231

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel